Paul J. Healey

2.7k total citations · 2 hit papers
29 papers, 1.9k citations indexed

About

Paul J. Healey is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Paul J. Healey has authored 29 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 14 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in Paul J. Healey's work include Inflammatory Bowel Disease (18 papers), Microscopic Colitis (14 papers) and Systemic Lupus Erythematosus Research (4 papers). Paul J. Healey is often cited by papers focused on Inflammatory Bowel Disease (18 papers), Microscopic Colitis (14 papers) and Systemic Lupus Erythematosus Research (4 papers). Paul J. Healey collaborates with scholars based in United States, Spain and United Kingdom. Paul J. Healey's co-authors include Julián Panés, Chinyu Su, William J. Sandborn, Wojciech Niezychowski, Séverine Vermeire, Bruce E. Sands, Geert D’Haens, Stefan Schreiber, Brian G. Feagan and Silvio Danese and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Gut.

In The Last Decade

Paul J. Healey

29 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

2017 1.2k citations William J. Sandborn, Chinyu Su et al. New England Journal of Medicine profile →
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

2017 296 citations Julián Panés, William J. Sandborn et al. Gut profile →

Peers

Paul J. Healey

GENET

EPIDE

IMMUN

RHEUM

SURGE

Wojciech Niezychowski United States

Gary Chan United States

Judith Collins United States

Pablo A. Olivera Argentina

Fumihito Hirai Japan

Jeffrey Axler United States

Ana P. Lacerda United States

Eric Vasiliauskas United States

Anne Camez United States

Sara Onali Italy

Wojciech Niezychowski United States

Paul J. Healey

1.9k ×1.5

GENET

1.2k ×1.4

EPIDE

686 ×1.4

IMMUN

422 ×1.1

RHEUM

535 ×1.5

SURGE

Citations per year, relative to Paul J. Healey Paul J. Healey (= 1×) peers Wojciech Niezychowski

Countries citing papers authored by Paul J. Healey

Since Specialization

Citations

This map shows the geographic impact of Paul J. Healey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul J. Healey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul J. Healey more than expected).

Fields of papers citing papers by Paul J. Healey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul J. Healey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul J. Healey. The network helps show where Paul J. Healey may publish in the future.

Co-authorship network of co-authors of Paul J. Healey

This figure shows the co-authorship network connecting the top 25 collaborators of Paul J. Healey. A scholar is included among the top collaborators of Paul J. Healey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul J. Healey. Paul J. Healey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yarlas, Aaron, Martha Bayliss, Joseph C. Cappelleri, et al.. (2017). Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. Quality of Life Research. 27(2). 273–290. 37 indexed citations

Panés, Julián, William J. Sandborn, Stefan Schreiber, et al.. (2017). Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 66(6). 1049–1059. 296 indexed citations breakdown →

Pasquale, Margaret K., Chinyu Su, Amy Marren, et al.. (2017). Ulcerative Colitis Treatment Patterns and Cost of Care. Value in Health. 20(6). 752–761. 31 indexed citations

Panés, Julián, David T. Rubin, Séverine Vermeire, et al.. (2017). P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis. Journal of Crohn s and Colitis. 11(suppl_1). S315–S317. 2 indexed citations

Pasquale, Margaret K., et al.. (2016). ULCERATIVE COLITIS TREATMENT PATTERNS AND COST OF CARE. Value in Health. 19(3). A314–A314. 1 indexed citations

Panés, Julián, Chinyu Su, Andrew G. Bushmakin, Joseph C. Cappelleri, & Paul J. Healey. (2016). Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. Journal of Crohn s and Colitis. 10(11). 1310–1315. 15 indexed citations

Wallace, Daniel J., Vibeke Strand, Joan T. Merrill, et al.. (2016). Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Annals of the Rheumatic Diseases. 76(3). 534–542. 98 indexed citations

Yarlas, Aaron, et al.. (2016). A Systematic Review of The SF-36® Health Survey for Measuring Health-Related Quality of Life In Patients with Ulcerative Colitis. Value in Health. 19(7). A514–A514. 1 indexed citations

Sandborn, William J., Bruce E. Sands, Geert D’Haens, et al.. (2016). OP019. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. Journal of Crohn s and Colitis. 10(suppl 1). S15.1–S15. 1 indexed citations

10.

Panés, Julián, William J. Sandborn, Stefan Schreiber, et al.. (2016). 855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial. Gastroenterology. 150(4). S182–S183. 10 indexed citations

11.

Panés, Julián, Chinyu Su, Andrew G. Bushmakin, et al.. (2015). Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterology. 15(1). 14–14. 74 indexed citations

12.

Panés, Julián, Chinyu Su, Andrew G. Bushmakin, Joseph C. Cappelleri, & Paul J. Healey. (2015). Sa1238 Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients With Ulcerative Colitis. Gastroenterology. 148(4). S–266. 1 indexed citations

13.

Smolen, Josef S, Serghei Popa, István Szombati, et al.. (2015). OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity. Annals of the Rheumatic Diseases. 74. 141–142. 2 indexed citations

14.

Larkin, James, Indra Tumur, Joseph C. Cappelleri, et al.. (2012). Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert Opinion on Pharmacotherapy. 14(1). 27–39. 19 indexed citations

15.

Yardley, Denise A., E. Claire Dees, Steve Myers, et al.. (2012). Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Research and Treatment. 136(3). 759–767. 21 indexed citations

16.

Mullins, C. Daniel, Prasun Subedi, Paul J. Healey, & Robert J. Sanchez. (2007). Economic Analysis of Triptan Therapy for Acute Migraine: A Medicaid Perspective. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(8). 1092–1101. 6 indexed citations

17.

Perfetto, Eleanor M., et al.. (2005). An Economic Evaluation of Triptan Products for Migraine. Value in Health. 8(6). 647–655. 15 indexed citations

18.

Healey, Paul J., et al.. (1979). Surgical management of the chronic venous ulcer: The rob procedure. The American Journal of Surgery. 137(4). 556–559. 9 indexed citations

19.

Bennett, John M. & Paul J. Healey. (1963). Spherocytic Hemolytic Anemia and Acute Cholecystitis Caused by Clostridium Welchii. New England Journal of Medicine. 268(19). 1070–1072. 10 indexed citations

20.

Berger, Robert L., Paul J. Healey, & John J. Byrne. (1962). Effect of Postganglionic Mesenteric Sympathectomy in Irreversible Hemorrhagic Shock.. Experimental Biology and Medicine. 110(2). 225–227. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact